Asymmetric organocatalysis: an enabling technology for medicinal chemistry

B Han, XH He, YQ Liu, G He, C Peng… - Chemical Society Reviews, 2021 - pubs.rsc.org
The efficacy and synthetic versatility of asymmetric organocatalysis have contributed
enormously to the field of organic synthesis since the early 2000s. As asymmetric …

Extracellular vesicles and particles impact the systemic landscape of cancer

S Lucotti, CM Kenific, H Zhang, D Lyden - The EMBO journal, 2022 - embopress.org
Intercellular cross talk between cancer cells and stromal and immune cells is essential for
tumor progression and metastasis. Extracellular vesicles and particles (EVPs) are a …

A comparative analysis of individual RAS mutations in cancer biology

C Muñoz-Maldonado, Y Zimmer, M Medová - Frontiers in oncology, 2019 - frontiersin.org
In human cells, three closely related RAS genes, termed HRAS, KRAS, and NRAS, encode
four highly homologous proteins. RAS proteins are small GTPases involved in a broad …

Targeting the ERK signaling pathway in melanoma

P Savoia, P Fava, F Casoni, O Cremona - International journal of …, 2019 - mdpi.com
The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its
progression have opened a new era in the treatment of this tumor. Vemurafenib was the first …

RAS-mediated oncogenic signaling pathways in human malignancies

AQ Khan, S Kuttikrishnan, KS Siveen, KS Prabhu… - Seminars in cancer …, 2019 - Elsevier
Abnormally activated RAS proteins are the main oncogenic driver that governs the
functioning of major signaling pathways involved in the initiation and development of human …

Targeting the small GTPase superfamily through their regulatory proteins

JL Gray, F von Delft, PE Brennan - … Chemie International Edition, 2020 - Wiley Online Library
The Ras superfamily of small GTPases are guanine‐nucleotide‐dependent switches
essential for numerous cellular processes. Mutations or dysregulation of these proteins are …

[HTML][HTML] Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives

S Liu, X Chen, T Lin - Journal of advanced research, 2022 - Elsevier
Background Chemotherapy is a first-line treatment for advanced and metastatic bladder
cancer, but the unsatisfactory objective response rate to this treatment yields poor 5-year …

Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer

JB Blaquier, AF Cardona, G Recondo - Frontiers in Oncology, 2021 - frontiersin.org
KRAS mutations are one of the most prevalent oncogenic alterations in cancer. Until
recently, drug development targeting KRAS did not convey clinical benefits to patients …

Surface molecules of extracellular vesicles secreted by the helminth pathogen Fasciola hepatica direct their internalisation by host cells

E de la Torre-Escudero, JQ Gerlach… - PLoS neglected …, 2019 - journals.plos.org
Helminth parasites secrete extracellular vesicles (EVs) that can be internalised by host
immune cells resulting in modulation of host immunity. While the molecular cargo of EVs …

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

G Yin, J Huang, J Petela, H Jiang, Y Zhang… - Signal transduction and …, 2023 - nature.com
Abstract Small GTPases including Ras, Rho, Rab, Arf, and Ran are omnipresent molecular
switches in regulating key cellular functions. Their dysregulation is a therapeutic target for …